Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.39 |
| ▸ | ESR1 | P03372 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990720 | 0.79 | APP (0.40) | — | |
| SCHEMBL18998250 | 0.79 | ADRA2A (0.40) | — | |
| SCHEMBL6797459 | 0.78 | DRD2 (0.43) | ESR2ESR1DRD2DRD1DRD3 | |
| SCHEMBL31541237 | 0.78 | ESR2 (0.38) | ESR2ESR1DRD2DRD1DRD3 | |
| SCHEMBL630543 | 0.77 | ESR1 (0.40) | ESR2ESR1DRD2DRD1DRD3 | |
| SCHEMBL6399115 | 0.76 | KDM4E (0.35) | — | |
| SCHEMBL6687949 | 0.76 | SIGMAR1 (0.40) | DRD2 | |
| SCHEMBL3982323 | 0.76 | DRD2 (0.45) | DRD2DRD3 | |
| SCHEMBL5523900 | 0.76 | ADRA2A (0.50) | DRD2DRD1DRD3DRD5DRD4 | |
| SCHEMBL3983449 | 0.76 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-07 | — | — | US | disclosed |
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-07 | — | — | US | disclosed |
| EP-3394050-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017109095-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017109095-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | ESR2 1538/4885ESR1 3492/4885DRD2 2371/4885 |
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | ESR2 422/4885ESR1 1538/4885DRD2 2356/4885 |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | ESR2 422/4885ESR1 1538/4885DRD2 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.